This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Bullous Diseases  • Prognosis/ Outcomes  • Pemphigoid  • Drug Therapy  • Drug Therapy, Other  • Immunology  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Jean-Claude Bystryn, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Beissert and colleagues¹ are to be commended for conducting one of the few randomized therapeutic trials on bullous pemphigoid. They conclude that mycophenolate mofetil is preferable to azathioprine when combined with oral methylprednisolone for the treatment of bullous pemphigoid because it is similarly effective but less toxic.

However, the opposite conclusion can be drawn from the data presented—that azathioprine is more effective and overall just as safe as mycophenolate mofetil. The time to induce complete remission, cumulative dose of steroids used, and duration of remission were all better in patients treated with azathioprine than in those treated with mycophenolate mofetil. The statistical significance of these findings was not analyzed, but some of the differences are impressive. The average time to induce complete remission was 50% shorter, and time to induce remission in 100% of patients was 3 times shorter in patients treated with azathioprine (n = 38) than in . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?